Current Report Filing (8-k)
May 01 2019 - 6:46AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 29, 2019
Frélii,
Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-107179
& 000-51210
|
|
980380519
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
2701
North Thanksgiving Way Suite 100, Lehi, UT 84043
(Address
of Principal Executive Offices)
(833)
437-3544
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01
Entry into a Material Definitive Agreement
Frelii,
Inc. has signed a contract and licensing agreement with Optivida Health (Optivida), one of the nation’s leaders in advanced
hemp extract and CBD for the consumer market. Optivida will leverage Frelii’s proprietary DNA Kit Packages™ to ensure
Optivida customers can realize the optimal benefits of the specific Optivida products that are best suited to the customers’
unique DNA profiles. Optivida will roll this out to its extensive customer base throughout North America over the next several
months.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Frélii,
Inc.
|
|
|
Date:
May 1, 2019
|
By:
|
/s/
Ian Jenkins
|
|
Name:
|
Ian
Jenkins
|
|
Title:
|
Chief
Executive Officer
|
Frlii (CE) (USOTC:FRLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Frlii (CE) (USOTC:FRLI)
Historical Stock Chart
From Sep 2023 to Sep 2024